Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...

A gold-standard University College of London study found a type of weight-loss jab had no benefit in alleviating a condition ...

Taryn Robertson, a professor at Randolph College, is currently fundraising and training to run a marathon for her father who ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

Traditional deep brain stimulation surgery can take up to 10 hours to complete, with the patient wide awake. This robotic ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

University of Tasmania and Parkinson's Research Foundation bridge gap in Parkinson's knowledge with first of its kind resourceFree online course ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...

A new platform for studying neuroinflammatory diseases, utilizing advanced 3D bioprinting technology has been developed.